MST1R

Summary

MST1R (macrophage stimulating 1 receptor, HGNC:7381) is a protein-coding gene on chromosome 3p21.31, encoding Macrophage-stimulating protein receptor (Q04912). Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand.

This gene encodes a cell surface receptor for macrophage-stimulating protein (MSP) with tyrosine kinase activity. The mature form of this protein is a heterodimer of disulfide-linked alpha and beta subunits, generated by proteolytic cleavage of a single-chain precursor. The beta subunit undergoes tyrosine phosphorylation upon stimulation by MSP. This protein is expressed on the ciliated epithelia of the mucociliary transport apparatus of the lung, and together with MSP, thought to be involved in host defense. Alternative splicing generates multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing.

Source: NCBI Gene 4486 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nasopharyngeal carcinoma, susceptibility to, 3 (Limited, GenCC)
• GWAS associations: 19
• Clinical variants (ClinVar): 269 total — 1 likely-pathogenic
• Phenotypes (HPO): 2
• Druggable target: yes — 42 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_002447

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7381
Approved symbol	MST1R
Name	macrophage stimulating 1 receptor
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	CDw136, CD136
Ensembl gene	ENSG00000164078
Ensembl biotype	protein_coding
OMIM	600168
Entrez	4486

Gene structure

Transcript identifiers

Ensembl transcripts: 33 — 23 protein_coding, 7 retained_intron, 3 nonsense_mediated_decay

ENST00000296474, ENST00000344206, ENST00000411578, ENST00000434765, ENST00000440292, ENST00000463789, ENST00000467110, ENST00000468525, ENST00000485044, ENST00000490053, ENST00000493535, ENST00000497001, ENST00000621387, ENST00000714251, ENST00000714252, ENST00000858906, ENST00000858907, ENST00000858908, ENST00000858909, ENST00000858910, ENST00000858911, ENST00000858912, ENST00000858913, ENST00000858914, ENST00000858915, ENST00000858916, ENST00000858917, ENST00000858918, ENST00000858919, ENST00000858920, ENST00000858921, ENST00000858922, ENST00000944850

RefSeq mRNA: 3 — MANE Select: NM_002447 NM_001244937, NM_001318913, NM_002447

CCDS: CCDS2807, CCDS58833, CCDS82777

Canonical transcript exons

ENST00000296474 — 20 exons

Exon	Start	End
ENSE00003292427	49895961	49896107
ENSE00003549554	49898867	49898995
ENSE00003566005	49898051	49898211
ENSE00003583713	49897520	49897685
ENSE00003603086	49899075	49899263
ENSE00003681115	49898518	49898688
ENSE00004023332	49895167	49895373
ENSE00004023333	49891197	49891306
ENSE00004023334	49890485	49890650
ENSE00004023335	49896729	49896890
ENSE00004023336	49891399	49891580
ENSE00004023337	49896540	49896633
ENSE00004023338	49897280	49897416
ENSE00004023341	49896195	49896404
ENSE00004023342	49895715	49895880
ENSE00004023343	49887002	49887562
ENSE00004023344	49902380	49903873
ENSE00004023345	49889924	49890060
ENSE00004023348	49891758	49891838
ENSE00004023349	49895447	49895548

Expression profiles

Bgee: expression breadth ubiquitous, 191 present calls, max score 97.15.

FANTOM5 (CAGE): breadth broad, TPM avg 1.3794 / max 95.6933, expressed in 399 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
42284	1.3794	399

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	97.15	gold quality
skin of leg	UBERON:0001511	94.27	gold quality
lower esophagus mucosa	UBERON:0035834	94.06	gold quality
skin of abdomen	UBERON:0001416	93.86	gold quality
rectum	UBERON:0001052	92.60	gold quality
body of stomach	UBERON:0001161	92.04	gold quality
transverse colon	UBERON:0001157	91.72	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.05	gold quality
zone of skin	UBERON:0000014	90.20	gold quality
ileal mucosa	UBERON:0000331	90.16	gold quality
gall bladder	UBERON:0002110	90.06	gold quality
esophagus mucosa	UBERON:0002469	89.40	gold quality
small intestine	UBERON:0002108	89.07	gold quality
stomach	UBERON:0000945	88.88	gold quality
mucosa of stomach	UBERON:0001199	87.84	gold quality
upper lobe of left lung	UBERON:0008952	87.10	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.02	gold quality
duodenum	UBERON:0002114	85.71	gold quality
upper lobe of lung	UBERON:0008948	85.35	gold quality
pancreatic ductal cell	CL:0002079	85.05	silver quality
intestine	UBERON:0000160	84.66	gold quality
colon	UBERON:0001155	83.86	gold quality
large intestine	UBERON:0000059	83.69	gold quality
fundus of stomach	UBERON:0001160	83.56	gold quality
right lung	UBERON:0002167	83.47	gold quality
colonic mucosa	UBERON:0000317	82.96	gold quality
apex of heart	UBERON:0002098	82.96	gold quality
esophagus	UBERON:0001043	82.57	gold quality
jejunal mucosa	UBERON:0000399	82.10	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	81.95	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.00
E-CURD-53	no	158.90

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EGR1, HIF1A, IRF6, NFE2L2, NFKB, NFKBIA, RELA, SMAD4, SP1, TXK

miRNA regulators (miRDB)

18 targeting MST1R, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-633	98.35	69.45	1167
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-7843-5P	98.12	65.26	1421
HSA-MIR-4632-5P	97.82	65.38	1470
HSA-MIR-6879-5P	97.77	65.52	1521
HSA-MIR-296-5P	97.61	64.02	851
HSA-MIR-6781-3P	97.44	66.85	970
HSA-MIR-2682-3P	97.10	66.16	840
HSA-MIR-874-5P	96.93	63.92	1014
HSA-MIR-3126-5P	96.87	65.83	912
HSA-MIR-6875-5P	96.87	65.49	958

Literature-anchored findings (GeneRIF, showing 40)

• overexpression of human wild-type RON causes the formation of lung tumors with unique biological characteristics in vivo (PMID:12214279)
• Transgenic mice in which surfactant protein C promoter was used to express human wild-type RON in distal lung epithelial cells developed multiple RON-expressing lung adenomas with distinct morphology & growth pattern which progressed to adenocarcinoma. (PMID:12419829)
• These data suggest that RON expression is altered in certain primary colon cancers. Abnormal accumulation of RON variants may play a role in the progression of certain colorectal cancers in vivo (PMID:12527888)
• HYAL2 receptor protein is associated with the RON receptor tyrosine kinase, rendering it functionally silent. (PMID:12676986)
• immunostaining and Western blot showed Ron in normal kidney and in all oncocytomas but never in renal cell carcinomas or in the renal carcinoma cell line Caki-1; Ron was expressed in phosphorylated, i.e., active, form (PMID:12766581)
• Ron tyrosine kinase receptor desensitization mediated by c-Cbl and its binding partner Grb2. (PMID:12802274)
• These data suggest that coexpression of the MET and RON receptors confer a selective advantage to ovarian cancer cells and might promote ovarian cancer progression. (PMID:12915129)
• Data show that macrophage stimulating protein (MSP) and its receptor (Ron) induce phosphorylation of both Ron and alpha6beta4 integrin, and result in activation of alpha3beta1 integrin. (PMID:12919677)
• the ron-sema domain can suppress the growth of macrophage-stimulating protein-responsive cells in culture (PMID:14597639)
• persistent RON expression and activation cause the loss of epithelial phenotypes (PMID:15001985)
• RON receptor can interact with each of the three members of the class B Plexins and control tumor invasive growth. (PMID:15184888)
• altered expression of RON in colon cancer cells is required to maintain tumorigenic phenotypes (PMID:15378025)
• Data suggest that RON initiates signaling pathways that negatively regulate HIV-1 transcription in monocytes/macrophages, and that HIV-1 suppresses RON function by decreasing protein levels in the brain to assure efficient replication. (PMID:15557181)
• Receptor RON and uts ligand macrophage stimulating protein are involved in the pathophysiology of endometriosis. (PMID:15764806)
• co-expression of RON and MET is associated with aggressive phenotype in node-negative breast cancer patients (PMID:15788670)
• The proto-oncogene, c-Cbl, which modulates ubiquitylation of RON, was increased in glia in both multiple sclerosis brains and experimental autoimmune encephalomyelitis spinal cords (PMID:15929040)
• altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity (PMID:16166096)
• Mst1r tyrosine kinase-domain deficient-mice have decreased survival times, alterations in cytokine and nitric oxide regulation, and an earlier onset of pulmonary pathology compared with control mice during acute lung injury (PMID:16166746)
• RON activation induced molecular and cellular alterations consistent with epithelial-mesenchymal (EMT) transition. (PMID:17311308)
• These data suggest that high molecular form hyaluronan is broken down by reactive oxygen species to form low-molecular-weight fragments that signal via RHAMM and RON to stimulate beat frequency. (PMID:17395888)
• overexpression of MSP, MT-SP1, and MST1R was a strong independent indicator of both metastasis and death in human breast cancer (PMID:17456594)
• This study reveals for the first time that RON alone is sufficient to induce complete and stabilized EMT in MDCK cells. (PMID:17588532)
• RONdelta170 is a naturally occurring variant with dominant negative activities and has potential for inhibiting RON-mediated tumorigenic activities in colorectal cancer cells. (PMID:17611409)
• RON receptor signaling may contribute to pancreatic carcinogenesis (PMID:17616662)
• high expression of Ron in the colorectal mucosa of ulcerative colitis patients suggests that this receptor might play roles in the pathophysiological background of this disease (PMID:18019691)
• Translocation of c-Met to the nucleus depends upon the adaptor protein Gab1 and importin beta1, and formation of Ca(2+) signals in turn depends upon this translocation (PMID:18073207)
• a clear link between Sp1-dependent RON tyrosine kinase expression and invasion of breast carcinoma cells. (PMID:18165235)
• the linkage disequilibrium with these functional MST1R variants implicate this gene as having a possible role in Crohn Disease pathogenesis. (PMID:18200509)
• RON activation differentially regulates claudin expression in epithelial cells (PMID:18204077)
• RON represses HIV transcription at multiple transcriptional check points including initiation, elongation and chromatin organization. (PMID:18209063)
• We found that RON was over expressed in bladder cancer but RON over expression was not associated with overall survival or other clinical parameters (PMID:18221954)
• loss of Smad4 contributes to aberrant RON expression and cross-talk of Smad4-independent TGF-beta signaling and the RON pathway promotes an invasive phenotype (PMID:18310076)
• The regulation of human RON gene expression by nuclear factor-kappaB; a potential therapeutic role for curcumin in blocking RON tyrosine kinase-mediated invasion of carcinoma cells. (PMID:18593918)
• study demonstrates that HIV-1 Tat targets the receptor tyrosine kinase recepteur d’origine nantais (RON), which negatively regulates inflammation & HIV transcription, for proteosome degradation (PMID:18606710)
• Ron is a critical factor in tumorigenesis. (PMID:18620091)
• RON has 2 alternative SRC-kinase-mediated modes of signaling that can contribute to oncogenic behavior in normal breast epithelial cells: an MSP-dependent increase in cell proliferation & migration and MSP-independent increased cell survival. (PMID:18836480)
• The entire C-terminus is required for RON or RON160-mediated intracellular signaling events leading to various cellular activities. (PMID:18950514)
• RON expression is significant in gastric carcinoma tissue and corresponding paraneoplastic tissue, but is not expressed in normal gastric mucosa. RON expression in gastric carcinoma tissue was not related to patient survival rates. (PMID:19040718)
• Results demonstrate that Ron plays an essential role in maintaining malignant phenotypes of colon cancer cells through regulating mutant PI3K activity. (PMID:19224914)
• RON is involved in mesangial cell proliferation under both physiological and pathological conditions (PMID:19242504)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	mst1rb	ENSDARG00000004871
danio_rerio	mst1ra	ENSDARG00000060235
mus_musculus	Mst1r	ENSMUSG00000032584
rattus_norvegicus	Mst1r	ENSRNOG00000032618

Paralogs (53): INSRR (ENSG00000027644), MUSK (ENSG00000030304), FLT4 (ENSG00000037280), EPHA3 (ENSG00000044524), ROS1 (ENSG00000047936), LTK (ENSG00000062524), ERBB3 (ENSG00000065361), TIE1 (ENSG00000066056), FGFR2 (ENSG00000066468), FGFR3 (ENSG00000068078), EPHA8 (ENSG00000070886), FGFR1 (ENSG00000077782), EPHA6 (ENSG00000080224), TYRO3 (ENSG00000092445), FLT1 (ENSG00000102755), MET (ENSG00000105976), EPHB6 (ENSG00000106123), PDGFRB (ENSG00000113721), EPHA4 (ENSG00000116106), TEK (ENSG00000120156), FLT3 (ENSG00000122025), KDR (ENSG00000128052), EPHB2 (ENSG00000133216), PDGFRA (ENSG00000134853), EPHA7 (ENSG00000135333), IGF1R (ENSG00000140443), NTRK3 (ENSG00000140538), ERBB2 (ENSG00000141736), EPHA2 (ENSG00000142627), EPHA5 (ENSG00000145242), EGFR (ENSG00000146648), EPHA1 (ENSG00000146904), NTRK2 (ENSG00000148053), MERTK (ENSG00000153208), EPHB1 (ENSG00000154928), KIT (ENSG00000157404), FGFR4 (ENSG00000160867), DDR2 (ENSG00000162733), RYK (ENSG00000163785), LMTK2 (ENSG00000164715)

Protein

Protein identifiers

Macrophage-stimulating protein receptor — Q04912 (reviewed: Q04912)

Alternative names: CDw136, Protein-tyrosine kinase 8, p185-Ron

All UniProt accessions (6): A0AAQ5BHR6, A0AAQ5BHX4, Q04912, H7C074, H7C3Z8, J3KQS7

UniProt curated annotations — full annotation on UniProt →

Function. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Also plays a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.

Subunit / interactions. Heterodimer of an alpha chain and a beta chain which are disulfide linked. Binds PLXNB1. Associates with and is negatively regulated by HYAL2. Interacts when phosphorylated with downstream effectors including PIK3R1, PCLG1, GRB2 and GAB1. Interacts with integrin beta1/ITGB1 in a ligand-independent fashion.

Subcellular location. Membrane.

Tissue specificity. Expressed in colon, skin, lung and bone marrow.

Post-translational modifications. Proteolytic processing yields the two subunits. Autophosphorylated in response to ligand binding on Tyr-1238 and Tyr-1239 in the kinase domain leading to further phosphorylation of Tyr-1353 and Tyr-1360 in the C-terminal multifunctional docking site. Ubiquitinated. Ubiquitination by CBL regulates the receptor stability and activity through proteasomal degradation. O-mannosylation of IPT/TIG domains on Thr or Ser residues by TMEM260 is required for protein maturation. O-mannosylated residues are composed of single mannose glycans that are not elongated or modified.

Disease relevance. Nasopharyngeal carcinoma, 3 (NPCA3) [MIM:617075] A form of nasopharyngeal carcinoma, a malignant neoplasm that originates in the nasopharyngeal epithelium and includes 4 subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and papillary adenocarcinoma. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Activity regulation. In its inactive state, the C-terminal tail interacts with the catalytic domain and inhibits the kinase activity. Upon ligand binding, the C-terminal tail is displaced and becomes phosphorylated, thus increasing the kinase activity.

Miscellaneous. Lacks part of the extracellular domain, oligomerizes and is constitutively activated. Expressed at higher level in cancer cells.

Similarity. Belongs to the protein kinase superfamily. Tyr protein kinase family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q04912-1	RON	yes
Q04912-2	Delta-RON, sf-RON
Q04912-3	RON-1
Q04912-4	RON-2
Q04912-5	RON-3
Q04912-6	RON-4
Q04912-7	RON-5

RefSeq proteins (3): NP_001231866, NP_001305842, NP_002438* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR001245	Ser-Thr/Tyr_kinase_cat_dom	Domain
IPR001627	Semap_dom	Domain
IPR002165	Plexin_repeat	Repeat
IPR002909	IPT_dom	Domain
IPR008266	Tyr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR014756	Ig_E-set	Homologous_superfamily
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR016201	PSI	Domain
IPR016244	Tyr_kinase_HGF/MSP_rcpt	Family
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR020635	Tyr_kinase_cat_dom	Domain
IPR036352	Semap_dom_sf	Homologous_superfamily
IPR039413	RON_Sema	Domain
IPR050122	RTK	Family

Pfam: PF01403, PF01437, PF01833, PF07714

Enzyme classification (BRENDA):

• EC 2.7.10.1 — receptor protein-tyrosine kinase (BRENDA: 44 organisms, 214 substrates, 574 inhibitors, 11 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0011–0.129	4
AC-DYFE-6-CHLORO-W-NHME	0.0051	1
AC-DYFGW-NHME	0.07	1
YFEW	0.232	1

Catalyzed reactions (Rhea), 1 shown:

• L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+) (RHEA:10596)

UniProt features (163 total): strand 57, helix 28, sequence variant 20, disulfide bond 11, glycosylation site 8, splice variant 8, turn 7, domain 5, binding site 4, modified residue 4, chain 3, topological domain 2, sequence conflict 2, signal peptide 1, region of interest 1, active site 1, transmembrane region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
4FWW	X-RAY DIFFRACTION	1.85
8ZKD	X-RAY DIFFRACTION	2.05
3PLS	X-RAY DIFFRACTION	2.24
4QT8	X-RAY DIFFRACTION	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q04912-F1	80.23	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 1208 (proton acceptor)

Ligand- & substrate-binding residues (4): 1088–1096; 1114; 1161–1164; 1212

Post-translational modifications (4): 1238, 1239, 1353, 1360

Disulfide bonds (11): 101–104, 107–162, 135–143, 174–177, 300–367, 385–407, 386–422, 527–545, 533–567, 536–552, 548–558

Glycosylation sites (8): 66, 419, 458, 488, 654, 720, 841, 897

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-8852405	Signaling by MST1
R-HSA-162582	Signal Transduction
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases

MSigDB gene sets: 195 (showing top): GOBP_SINGLE_FERTILIZATION, GOBP_REGULATION_OF_PHOSPHORYLATION, MODULE_255, GOBP_RESPONSE_TO_PEPTIDE, JAEGER_METASTASIS_DN, MODULE_64, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, MODULE_317, GOCC_CELL_SURFACE, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_VESICLE_MEDIATED_TRANSPORT, HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_DN, KANG_FLUOROURACIL_RESISTANCE_DN, MARTINEZ_RB1_TARGETS_UP, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY

GO Biological Process (16): phagocytosis (GO:0006909), defense response (GO:0006952), signal transduction (GO:0007165), cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169), single fertilization (GO:0007338), nervous system development (GO:0007399), positive regulation of cell population proliferation (GO:0008284), response to virus (GO:0009615), cell migration (GO:0016477), positive regulation of MAP kinase activity (GO:0043406), innate immune response (GO:0045087), positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051897), immune system process (GO:0002376), protein phosphorylation (GO:0006468), macrophage colony-stimulating factor signaling pathway (GO:0038145), semaphorin-plexin signaling pathway (GO:0071526)

GO Molecular Function (11): transmembrane receptor protein tyrosine kinase activity (GO:0004714), macrophage colony-stimulating factor receptor activity (GO:0005011), ATP binding (GO:0005524), enzyme binding (GO:0019899), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein tyrosine kinase activity (GO:0004713), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), semaphorin receptor activity (GO:0017154)

GO Cellular Component (6): stress fiber (GO:0001725), vacuole (GO:0005773), plasma membrane (GO:0005886), cell surface (GO:0009986), signaling receptor complex (GO:0043235), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Signaling by Receptor Tyrosine Kinases	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
endocytosis	1
response to stress	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
enzyme-linked receptor protein signaling pathway	1
fertilization	1
system development	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
response to other organism	1
cell motility	1
MAP kinase activity	1
regulation of MAP kinase activity	1
positive regulation of MAPK cascade	1
positive regulation of protein serine/threonine kinase activity	1
immune response	1
defense response to symbiont	1
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
positive regulation of intracellular signal transduction	1
biological_process	1
phosphorylation	1
protein modification process	1
cytokine-mediated signaling pathway	1
cellular response to macrophage colony-stimulating factor stimulus	1
cell surface receptor signaling pathway	1
protein tyrosine kinase activity	1
transmembrane receptor protein kinase activity	1
transmembrane receptor protein tyrosine kinase activity	1
macrophage colony-stimulating factor signaling pathway	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
protein binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1

Protein interactions and networks

STRING

2840 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MST1R	MST1	P26927	999
MST1R	HGF	P14210	926
MST1R	SRSF1	Q07955	849
MST1R	HYAL2	Q12891	823
MST1R	EGFR	P00533	772
MST1R	CTNNB1	P35222	743
MST1R	SPAM1	P38567	742
MST1R	GAB2	Q9UQC2	704
MST1R	HNRNPA1	P09651	637
MST1R	PLXNB1	O43157	632
MST1R	HYAL1	Q12794	586
MST1R	ATAD1	Q8NBU5	564
MST1R	SEMA3B	Q13214	507
MST1R	APEH	P13798	506
MST1R	SEMA6A	Q9H2E6	503

IntAct

38 interactions, top by confidence:

A	B	Type	Score
MST1R	MST1	psi-mi:“MI:0407”(direct interaction)	0.720
MST1R	MST1	psi-mi:“MI:0915”(physical association)	0.720
MST1	MST1R	psi-mi:“MI:0407”(direct interaction)	0.720
PLXNB1	MST1R	psi-mi:“MI:0915”(physical association)	0.520
PLXNB2	MST1R	psi-mi:“MI:0915”(physical association)	0.520
MST1R	PLXNB3	psi-mi:“MI:0915”(physical association)	0.520
MST1R	PLXNB1	psi-mi:“MI:0915”(physical association)	0.520
MST1R	PLXNB2	psi-mi:“MI:0915”(physical association)	0.520
FURIN	MST1R	psi-mi:“MI:0194”(cleavage reaction)	0.440
MST1R	CBL	psi-mi:“MI:0407”(direct interaction)	0.440
PKM	MST1R	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
MST1R	UBL4A	psi-mi:“MI:0914”(association)	0.420
MST1R	Plxnb1	psi-mi:“MI:0915”(physical association)	0.400
YWHAQ	MST1R	psi-mi:“MI:0915”(physical association)	0.370
	ABL1	psi-mi:“MI:0914”(association)	0.350
TMEM106A	QSOX1	psi-mi:“MI:0914”(association)	0.350
TMEM106A	TMEM131L	psi-mi:“MI:0914”(association)	0.350
BTNL2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
SFTPC	TMEM131L	psi-mi:“MI:0914”(association)	0.350
BRICD5	TMEM131L	psi-mi:“MI:0914”(association)	0.350
HLA-DRB1	TMEM131L	psi-mi:“MI:0914”(association)	0.350
PTCH1	TMEM131L	psi-mi:“MI:0914”(association)	0.350
ASIC4	TMEM131L	psi-mi:“MI:0914”(association)	0.350
NCR3	POTEF	psi-mi:“MI:0914”(association)	0.350
NAAA	HAX1	psi-mi:“MI:0914”(association)	0.350
PRG2	QSOX1	psi-mi:“MI:0914”(association)	0.350

BioGRID (205): MST1R (Affinity Capture-MS), MST1R (Affinity Capture-MS), MST1R (Affinity Capture-MS), MST1R (Affinity Capture-MS), MST1R (Affinity Capture-MS), PTPRR (Two-hybrid), MST1R (Negative Genetic), MST1R (Negative Genetic), PRKCA (Negative Genetic), MST1R (Negative Genetic), MST1R (Positive Genetic), PRKAB1 (Positive Genetic), MST1R (Positive Genetic), PFKFB4 (Positive Genetic), NPY4R (Positive Genetic)

ESM2 similar proteins: A0A1B0GTW7, A0A1D5NSK0, A0A1L8HYT7, A0A286YEC0, D3ZT86, D3ZWJ9, D4A929, F8W3R9, G7PWZ3, I6M4H4, O08852, O43157, O43278, O75074, O88204, P17813, P49000, P59383, Q04912, Q17R55, Q499Z3, Q4R3B7, Q4TUC0, Q5ND34, Q62190, Q63961, Q6AXX1, Q76MJ5, Q7TN88, Q7TQH7, Q7Z442, Q7Z4F1, Q80W87, Q80YN4, Q866Y3, Q86VZ4, Q8BHW9, Q8BMN4, Q8BYI8, Q8BZT7

Diamond homologs: A0JM20, A0M8R7, A0M8S8, A1X150, F1QVU0, G3V9H8, O02466, O35346, P00519, P00520, P00521, P00522, P00529, P06213, P07949, P08069, P08581, P08941, P09760, P0DV84, P10447, P13368, P14617, P16056, P20806, P22182, P23049, P30530, P33497, P34152, P34925, P35546, P35590, P42684, P55144, P55146, P57097, P70451, P97523, P97793

SIGNOR signaling

9 interactions.

A	Effect	B	Mechanism
AKT	up-regulates	MST1R	phosphorylation
N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-3-pyridinecarboxamide	down-regulates	MST1R	“chemical inhibition”
N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamide	down-regulates	MST1R	“chemical inhibition”
MK-2461	down-regulates	MST1R	“chemical inhibition”
AKT1	up-regulates	MST1R	phosphorylation
MST1R	“up-regulates activity”	CTNNB1	phosphorylation
EGFR	“up-regulates activity”	MST1R	phosphorylation
MST1	up-regulates	MST1R	binding
MST1R	“up-regulates activity”	ABL1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

269 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	192
Likely benign	27
Benign	16

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
800321	NM_002447.4(MST1R):c.1477G>T (p.Asp493Tyr)	Likely pathogenic

SpliceAI

3675 predictions. Top by Δscore:

Variant	Effect	Δscore
3:49887559:GTACC:G	acceptor_loss	1.0000
3:49887560:TACC:T	acceptor_loss	1.0000
3:49887561:ACC:A	acceptor_loss	1.0000
3:49887562:CCT:C	acceptor_loss	1.0000
3:49887563:C:CA	acceptor_loss	1.0000
3:49887564:T:A	acceptor_loss	1.0000
3:49890481:TCACC:T	donor_loss	1.0000
3:49890482:CACCA:C	donor_loss	1.0000
3:49890483:ACCAC:A	donor_loss	1.0000
3:49890484:CCA:C	donor_gain	1.0000
3:49890652:T:C	acceptor_gain	1.0000
3:49890652:T:TC	acceptor_gain	1.0000
3:49891185:CTGG:C	donor_gain	1.0000
3:49891195:A:AC	donor_gain	1.0000
3:49891196:C:CC	donor_gain	1.0000
3:49891394:CTGA:C	donor_loss	1.0000
3:49891395:TGACC:T	donor_loss	1.0000
3:49891396:GACC:G	donor_loss	1.0000
3:49891398:CCCG:C	donor_gain	1.0000
3:49895223:T:TA	donor_gain	1.0000
3:49895263:G:C	donor_gain	1.0000
3:49895374:C:CC	acceptor_gain	1.0000
3:49895457:T:TA	donor_gain	1.0000
3:49897417:CTA:C	acceptor_loss	1.0000
3:49898207:TGGAA:T	acceptor_gain	1.0000
3:49898208:GGAA:G	acceptor_gain	1.0000
3:49898212:C:CC	acceptor_gain	1.0000
3:49898685:AAAC:A	acceptor_gain	1.0000
3:49898686:AAC:A	acceptor_gain	1.0000
3:49898689:C:CC	acceptor_gain	1.0000

AlphaMissense

9011 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:49891768:C:A	K1114N	0.997
3:49891768:C:G	K1114N	0.997
3:49890060:A:G	W1271R	0.996
3:49890060:A:T	W1271R	0.996
3:49890521:G:C	S1258R	0.996
3:49890521:G:T	S1258R	0.996
3:49890523:T:G	S1258R	0.996
3:49890538:A:G	W1253R	0.996
3:49890538:A:T	W1253R	0.996
3:49890039:A:G	W1278R	0.995
3:49890039:A:T	W1278R	0.995
3:49890503:A:C	F1264L	0.995
3:49890503:A:T	F1264L	0.995
3:49890505:A:G	F1264L	0.995
3:49890032:A:G	L1280P	0.994
3:49890536:C:A	W1253C	0.993
3:49890536:C:G	W1253C	0.993
3:49890630:A:T	V1222D	0.993
3:49891287:A:G	L1185P	0.993
3:49891775:G:T	A1112D	0.993
3:49902927:A:C	F228C	0.993
3:49887540:A:G	W1324R	0.992
3:49887540:A:T	W1324R	0.992
3:49891823:A:T	V1096D	0.992
3:49891831:A:C	F1093L	0.992
3:49891831:A:T	F1093L	0.992
3:49891833:A:G	F1093L	0.992
3:49891829:C:T	G1094E	0.991
3:49903182:C:G	C143S	0.991
3:49903183:A:T	C143S	0.991

dbSNP variants (sampled 300 via entrez): RS1000195236 (3:49892506 G>A,C), RS1000283859 (3:49898473 C>T), RS1000344143 (3:49890965 A>G), RS1000572102 (3:49890928 G>A), RS1000592373 (3:49898370 T>G), RS1000602560 (3:49901954 A>C,G,T), RS1000884012 (3:49904327 G>T), RS1001079569 (3:49904611 G>A,T), RS1001193344 (3:49894282 G>C), RS1001245372 (3:49894106 T>C), RS1001339313 (3:49887842 C>T), RS1001464861 (3:49898065 G>A,T), RS1001672888 (3:49897569 T>A), RS1001709515 (3:49900871 G>A), RS1001963672 (3:49903908 G>A,C,T)

Disease associations

OMIM: gene MIM:600168 | disease phenotypes: MIM:617075, MIM:254500

GenCC curated gene-disease

Disease	Classification	Inheritance
nasopharyngeal carcinoma, susceptibility to, 3	Limited	Autosomal dominant

Mondo (2): nasopharyngeal carcinoma, susceptibility to, 3 (MONDO:0014902), plasma cell myeloma (MONDO:0009693)

Orphanet (3): Nasopharyngeal carcinoma (Orphanet:150), Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0100630	Neoplasia of the nasopharynx

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST001725_77	Inflammatory bowel disease	1.000000e-47
GCST002548_9	Ulcerative colitis	8.000000e-07
GCST003795_3	Age at first birth	5.000000e-15
GCST005951_49	Body mass index	1.000000e-08
GCST006044_2	Age at first birth	2.000000e-06
GCST006045_5	Age at first birth	6.000000e-10
GCST006920_7	Regular attendance at a gym or sports club	6.000000e-10
GCST006922_9	Regular attendance at a religious group	3.000000e-08
GCST007044_11	Extremely high intelligence	4.000000e-08
GCST007559_24	Sleep duration (short sleep)	3.000000e-08
GCST008129_41	Body mass index	9.000000e-26
GCST010002_422	Refractive error	4.000000e-14
GCST010698_80	Subcortical volume (min-P)	3.000000e-24
GCST010699_110	Brain morphology (min-P)	4.000000e-08
GCST010701_52	Cortical surface area (MOSTest)	1.000000e-16
GCST010702_36	Subcortical volume (MOSTest)	1.000000e-10
GCST010703_262	Brain morphology (MOSTest)	2.000000e-13
GCST010988_142	Adult body size	2.000000e-37
GCST011122_43	Walking pace	6.000000e-16

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0009101	age at first birth measurement
EFO:0004340	body mass index
EFO:0009592	social interaction measurement
EFO:0004337	intelligence
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2689 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

42 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 155,553 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1173655	AFATINIB	4	15,144
CHEMBL180022	NERATINIB	4	9,404
CHEMBL1834657	INFIGRATINIB PHOSPHATE	4	285
CHEMBL1852688	INFIGRATINIB	4	2,209
CHEMBL189963	PALBOCICLIB	4	13,102
CHEMBL1983268	ENTRECTINIB	4	3,510
CHEMBL2103830	FOSTAMATINIB	4	3,841
CHEMBL2105717	CABOZANTINIB	4	11,177
CHEMBL24828	VANDETANIB	4	42,230
CHEMBL288441	BOSUTINIB	4	12,255
CHEMBL3301622	GILTERITINIB	4	2,395
CHEMBL601719	CRIZOTINIB	4	14,403
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL415049	BARASERTIB	3	2,371
CHEMBL491473	CEDIRANIB	3	9,098
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL1230609	FORETINIB	2	3,096
CHEMBL1738757	REBASTINIB	2	1,478
CHEMBL1822792	MK-2461	2	686
CHEMBL1967878	CENISERTIB	2
CHEMBL1980297	ILORASERTIB	2
CHEMBL215152	DEFOSBARASERTIB	2
CHEMBL253969	OSI-632	2
CHEMBL3039525	GOLVATINIB	2
CHEMBL3545307	MERESTINIB	2
CHEMBL3989914	GLESATINIB	2
CHEMBL460702	BMS-777607	2
CHEMBL475251	R-406	2
CHEMBL564829	MILCICLIB	2

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Type X RTKs: HGF (hepatocyte growth factor) receptor family

Most potent curated ligand interactions (5 total), top 5:

Ligand	Action	Affinity	Parameter
BMS-777607	Inhibition	8.74	pIC50
compound 19a [PMID: 30503936]	Inhibition	8.54	pIC50
MK-2461	Inhibition	8.15	pIC50
merestinib	Inhibition	7.92	pIC50
compound 8i [PMID: 22765894]	Inhibition	6.91	pIC50

Binding affinities (BindingDB)

7 measured of 9 human assays (9 total across all organisms); most potent 7 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
FORETINIB	IC50	1.9 nM
(3R,4R)-3-methoxy-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	IC50	3.93 nM	US-10189849: CDK inhibitors
N-[3-fluoro-4-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]phenyl]-1-phenyl-5-(trifluoromethyl)pyrazole-4-carboxamide	IC50	4.3 nM	US-9283225: Pyrido-pyrimidine derivatives
N-[3-fluoro-4-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]phenyl]-5-methyl-1-phenylpyrazole-4-carboxamide	IC50	10 nM	US-9283225: Pyrido-pyrimidine derivatives
N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-5-ethyl-1-pyrimidin-5-ylpyrazole-4-carboxamide	IC50	30 nM	US-9481668: Quinoline inhibitor of the macrophage stimulating 1 receptor MSTR1
4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide	IC50	33 nM
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide	KD	1000 nM

ChEMBL bioactivities

354 potent at pChembl≥5 of 383 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.80	IC50	0.16	nM	CHEMBL5430218
9.60	Ki	0.2512	nM	CHEMBL1980995
9.59	IC50	0.26	nM	CHEMBL5427445
9.55	IC50	0.28	nM	CHEMBL5419134
9.41	IC50	0.39	nM	CHEMBL5396164
9.39	IC50	0.41	nM	CHEMBL5404435
9.32	IC50	0.48	nM	CHEMBL5421161
9.32	IC50	0.48	nM	CHEMBL5411457
9.31	IC50	0.49	nM	CHEMBL5440908
9.21	IC50	0.62	nM	CHEMBL5398932
9.20	IC50	0.63	nM	CHEMBL5397231
9.16	IC50	0.69	nM	CHEMBL5431928
9.14	IC50	0.73	nM	CHEMBL5424053
9.14	IC50	0.72	nM	CHEMBL5436390
9.13	IC50	0.74	nM	CHEMBL5437130
9.09	IC50	0.82	nM	CHEMBL5405709
9.09	IC50	0.81	nM	CHEMBL5400656
9.07	IC50	0.86	nM	CHEMBL5411204
9.01	IC50	0.98	nM	CHEMBL5431851
9.00	Ki	1	nM	CHEMBL2031893
8.92	IC50	1.2	nM	MERESTINIB
8.89	Ki	1.3	nM	CHEMBL447602
8.80	Ki	1.585	nM	CHEMBL1980407
8.74	IC50	1.8	nM	BMS-777607
8.74	IC50	1.8	nM	CHEMBL4753082
8.74	IC50	1.82	nM	CHEMBL5429072
8.69	IC50	2.05	nM	FORETINIB
8.69	IC50	2.04	nM	CHEMBL5395266
8.67	IC50	2.15	nM	CHEMBL5400847
8.65	IC50	2.25	nM	CHEMBL5399763
8.64	IC50	2.28	nM	CHEMBL5429366
8.62	IC50	2.39	nM	CHEMBL5409449
8.62	IC50	2.39	nM	CHEMBL5395573
8.59	IC50	2.55	nM	CHEMBL5429043
8.55	IC50	2.83	nM	CHEMBL5438831
8.54	IC50	2.9	nM	CHEMBL4587222
8.52	IC50	3	nM	FORETINIB
8.52	Kd	3	nM	FORETINIB
8.51	IC50	3.1	nM	CHEMBL4171115
8.46	IC50	3.43	nM	FORETINIB
8.46	IC50	3.48	nM	FORETINIB
8.45	IC50	3.54	nM	FORETINIB
8.44	IC50	3.62	nM	FORETINIB
8.41	IC50	3.92	nM	FORETINIB
8.40	Ki	3.981	nM	CENISERTIB
8.37	IC50	4.3	nM	CHEMBL3899652
8.26	IC50	5.47	nM	CHEMBL5425777
8.26	IC50	5.5	nM	CRIZOTINIB
8.24	IC50	5.71	nM	CHEMBL5433417
8.22	IC50	6	nM	CHEMBL5394757

PubChem BioAssay actives

219 with measured affinity, of 1597 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-ethoxy-N-[3-fluoro-4-[2-[5-[(3-methoxyazetidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0002	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(4-methylpiperazin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0003	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0003	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0004	uM
4-ethoxy-N-[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0004	uM
N-[4-[2-[5-[(3,3-difluoroazetidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0005	uM
N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxo-4-propoxypyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0005	uM
4-ethoxy-1-(4-fluorophenyl)-N-[3-fluoro-4-(2-pyridin-2-ylthieno[3,2-b]pyridin-7-yl)oxyphenyl]-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0005	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(3-fluoroazetidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0006	uM
N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-4-(2-methylpropoxy)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0006	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(4-methoxypiperidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0007	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(3-methoxypyrrolidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0007	uM
4-(2-cyclopropylethoxy)-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0007	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(3-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0007	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-2-oxo-1-phenylpyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0008	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(3-fluoropyrrolidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0008	uM
N-[4-[2-[5-[(3,3-difluoropyrrolidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0009	uM
4-butoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0010	uM
N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-1,5-dimethyl-3-oxo-2-phenylpyrazole-4-carboxamide	662101: Inhibition of RON by HTRF assay	ki	0.0010	uM
N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide	1533355: Inhibition of RON (unknown origin) by FISH assay	ic50	0.0012	uM
2-(4-fluoroanilino)-5-[5-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy-2-pyridinyl]-3-methylpyrimidin-4-one	364260: Inhibition of phosphorylated RON	ki	0.0013	uM
N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-4-methoxy-2-oxopyridine-3-carboxamide	1691612: Inhibition of Ron (unknown origin)	ic50	0.0018	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(4-fluoropiperidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0018	uM
N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	1534900: Inhibition of RON (unknown origin)	ic50	0.0018	uM
1-[(2S)-2-(2,4-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[4-[7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinolin-4-yl]oxy-3,5-difluorophenyl]urea	1986472: Inhibition of RON (unknown origin) by kinome scan assay	ic50	0.0020	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	1986472: Inhibition of RON (unknown origin) by kinome scan assay	ic50	0.0021	uM
4-[2-(dimethylamino)ethoxy]-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0022	uM
N-[3,5-difluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0022	uM
N-[3-chloro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0023	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(2-morpholin-4-ylethoxy)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0024	uM
1-[2-(2,4-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[4-[7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinolin-4-yl]oxy-3,5-difluorophenyl]urea	1986472: Inhibition of RON (unknown origin) by kinome scan assay	ic50	0.0024	uM
1-(4-chlorophenyl)-4-ethoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0026	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(2-morpholin-4-ylethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0028	uM
1-[2-(2,6-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[4-[7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinolin-4-yl]oxy-3,5-difluorophenyl]urea	1533587: Inhibition of Ron (unknown origin) using FAM-labelled peptide and ATP incubated for 10 mins by mobility shift assay	ic50	0.0029	uM
N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-5-(4-fluorophenyl)-4-oxo-1H-pyridine-3-carboxamide	1276923: Inhibition of Ron (unknown origin)	ic50	0.0030	uM
1-[2-(2,6-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[2-fluoro-4-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-yl]oxyphenyl]urea	1352741: Inhibition of Ron (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA	ic50	0.0031	uM
4-[[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]iminomethyl]-5-methyl-2-[2-(trifluoromethyl)phenyl]-1H-pyrazol-3-one	1800438: HTRF kinase assay from Article 10.1016/j.bioorg.2014.07.011: “Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.”	ic50	0.0042	uM
Crizotinib	2161836: Inhibition of human N-terminal GST-fused RON cytoplasmic domain (979 to 1400(end) residues) expressed in baculovirus expression system using Srctide as substrate measured after 1 hr by off-chip mobility shift assay relative to control	ic50	0.0055	uM
N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-4-(1-methylpyrrolidin-3-yl)oxy-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0055	uM
1-[(2R)-2-(2,4-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[4-[7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinolin-4-yl]oxy-3,5-difluorophenyl]urea	1986472: Inhibition of RON (unknown origin) by kinome scan assay	ic50	0.0057	uM
N-[4-[2-[5-[(4,4-difluoropiperidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0060	uM
14-(dimethylsulfamoylamino)-5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene	728081: Inhibition of RON (unknown origin) by TR-FRET assay	ic50	0.0070	uM
14-[[[(2R)-1,4-dioxan-2-yl]methyl-methylsulfamoyl]amino]-5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene	606069: Inhibition of human Ron	ic50	0.0070	uM
1-[5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-14-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide	1534900: Inhibition of RON (unknown origin)	ic50	0.0070	uM
N-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide	2015471: Inhibition of RON (unknown origin)	ic50	0.0090	uM
N-[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-phenyl-2-(trifluoromethyl)pyrrole-3-carboxamide	1228792: Inhibition of RON (unknown origin) transfected in 293T cells assessed as autophosporylated level by ELISA	ic50	0.0100	uM
1-(2-hydroxy-2-methylpropyl)-N-[5-(7-methoxyquinolin-4-yl)oxy-2-pyridinyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide	662101: Inhibition of RON by HTRF assay	ic50	0.0100	uM
N-[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-phenyl-5-(trifluoromethyl)pyrazole-4-carboxamide	1241723: Inhibition of human RON	ic50	0.0100	uM
N-[2-chloro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0103	uM
N-[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-phenyl-5-(trifluoromethyl)imidazole-4-carboxamide	1228792: Inhibition of RON (unknown origin) transfected in 293T cells assessed as autophosporylated level by ELISA	ic50	0.0130	uM

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Aflatoxin B1	decreases methylation, increases expression	2
methyleugenol	increases expression	1
pirinixic acid	increases activity, affects binding, decreases expression	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
pyrrolidine dithiocarbamic acid	decreases expression	1
benzo(e)pyrene	decreases methylation	1
cupric chloride	increases expression	1
nickel sulfate	decreases expression, increases expression	1
pentanal	increases expression	1
jinfukang	increases expression	1
NSC 689534	increases expression	1
5H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one	decreases activity	1
Arsenic Trioxide	decreases response to substance	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Curcumin	increases expression, decreases expression, affects binding, decreases reaction	1
Methapyrilene	decreases methylation	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Valproic Acid	decreases expression, increases methylation	1
Vanadium	decreases expression	1
Asbestos, Crocidolite	decreases expression	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	increases expression	1

ChEMBL screening assays

384 unique, capped per target: 382 binding, 2 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1006336	Binding	Inhibition of Tel-fused RON kinase-mediated mouse BaF3 cell proliferation	Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. — Proc Natl Acad Sci U S A
CHEMBL1964103	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MST1R	PubChem BioAssay data set

Cellosaurus cell lines

4 cell lines: 3 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C7DA	Abcam A-549 MST1R KO	Cancer cell line	Male
CVCL_C7E0	Abcam HCT 116 MST1R KO	Cancer cell line	Male
CVCL_D3UF	MDCK-RE7	Spontaneously immortalized cell line	Female
CVCL_D7VC	Ubigene A-549 MST1R KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00104104	PHASE4	COMPLETED	A Multiple Myeloma Trial in Patients With Bone Metastases
NCT00211211	PHASE4	COMPLETED	FREE Study - Fracture Reduction Evaluation
NCT00242528	PHASE4	WITHDRAWN	Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
NCT00257114	PHASE4	COMPLETED	Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00352703	PHASE4	COMPLETED	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
NCT00361140	PHASE4	COMPLETED	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
NCT00622505	PHASE4	COMPLETED	Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
NCT00652041	PHASE4	COMPLETED	Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
NCT00733538	PHASE4	COMPLETED	Stage I Multiple Myeloma Treatment
NCT01087008	PHASE4	COMPLETED	Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01249690	PHASE4	UNKNOWN	Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
NCT01410929	PHASE4	WITHDRAWN	Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma
NCT01731886	PHASE4	COMPLETED	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01868828	PHASE4	UNKNOWN	A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
NCT02268890	PHASE4	COMPLETED	A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
NCT02286830	PHASE4	COMPLETED	Prolonged Protection From Bone Disease in Multiple Myeloma
NCT02559154	PHASE4	UNKNOWN	Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02577783	PHASE4	UNKNOWN	PDD vs PAD to Treat Initially Diagnosed MM
NCT02773550	PHASE4	TERMINATED	Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
NCT02958969	PHASE4	COMPLETED	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
NCT03173092	PHASE4	TERMINATED	A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
NCT03619252	PHASE4	COMPLETED	Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
NCT03768960	PHASE4	COMPLETED	A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT03829371	PHASE4	ACTIVE_NOT_RECRUITING	STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT03908138	PHASE4	UNKNOWN	RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
NCT04217967	PHASE4	COMPLETED	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
NCT04952766	PHASE4	COMPLETED	Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
NCT04989140	PHASE4	UNKNOWN	Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT05183139	PHASE4	WITHDRAWN	A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
NCT05201781	PHASE4	RECRUITING	A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05429515	PHASE4	NOT_YET_RECRUITING	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
NCT05511428	PHASE4	COMPLETED	Home Based Daratumumab Administration for Patients With Multiple Myeloma
NCT05545202	PHASE4	UNKNOWN	A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
NCT05555329	PHASE4	COMPLETED	Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
NCT05722405	PHASE4	RECRUITING	Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05855122	PHASE4	UNKNOWN	Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05944783	PHASE4	NOT_YET_RECRUITING	Bioequivalence Studies of Dasatinib 100 Mg
NCT06057402	PHASE4	RECRUITING	Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06251076	PHASE4	RECRUITING	Plan Development for Giving Teclistamab in the Outpatient Setting